The endocannabinoid system is a major player in schizophrenia

Cannabinoids and the Brain

Volumn , Issue , 2008, Pages 485-528

  Köfalvi, Attila ^b   Fritzsche, Markus ^a  

^a Praxis für Innere Medizin ^*  (Switzerland)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649923568     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74349-3_22     Document Type: Chapter

References (250)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202.
2. Aldrich MR (1977) Tantric cannabis use in India. J Psychedelic Drugs 9:227-233.
3. Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA, Svenningsson P, Fredholm BB, Borrelli E, Greengard P, Fisone G (2005) Cannabinoid action depends on phosphorylation of dopamine- And cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25:8432-8438.
4. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486.
5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212-1213.
6. Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110-117.
7. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP (2003) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53:56-64.
8. Baldelli P, Hernandez-Guijo JM, Carabelli V, Carbone E (2005) Brain-derived neurotrophic factor enhances GABA release probability and nonuniform distribution of N- And P/Q-type channels on release sites of hippocampal inhibitory synapses. J Neurosci 25:3358-3368.
9. Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P (2007) Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32:2098-2107.
10. Bär KJ, Letzsch A, Jochum T, Wagner G, Greiner W, Sauer H (2005) Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res 39:519-527.
11. Baudelaire C (1966) Les Paradis Artificiels. Paris: Garnier-Flammarion.
12. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102:19115-191120.
13. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316:1212-1216.
14. 2+ connection in dopamine signaling. Trends Pharmacol Sci 24:486-492.
15. Berridge MJ (1998) Neuronal calcium signaling. Neuron 21:13-26.
16. Betz VA (1875) Two centers in the human brain cortex.
17. Blackwood D (2000) P300, a state and a trait marker in schizophrenia. Lancet 355:771-72.
18. Bleuler E (1911) Handbuch der Psychiatrie. Dementia praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke.
19. 1 allele. Pharmacogenetics 4:313-322.
20. Boksa P (2007) Of rats and schizophrenia. J Psychiatry Neurosci 32:8-10.
21. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T (2007) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192:325-336.
22. Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, Farrell M, Murray RM (2006) Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med 36:1441-1446.
23. Brakeman PR, Lanahan AA, O'Brien R, Roche K, Barnes CA, Huganir RL, Worley PF (1997) Homer: A protein that selectively binds metabotropic glutamate receptors. Nature 368:284-288.
24. Brown P, Williams D, Aziz T, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V (2002) Pallidal activity recorded in patients with implanted electrodes predictively correlates with eventual performance in a timing task. Neurosci Lett 330:188-192.
25. Buhusi CV, Meck WH (2005) What makes us tick? Functional and neural mechanisms of interval timing. Nat Rev Neurosci 6:755-765.
26. Burgoyne RD, O'Callaghan DW, Hasdemir B, Haynes LP, Tepikin AV (2004) Neuronal Ca2+-sensor proteins: Multitalented regulators of neuronal function. Trends Neurosci 27:203-209.
27. Cannon TD, Thompson PM, van Erp TG, Toga AW, Poutanen VP, Huttunen M, Lonnqvist J, Standerskjold-Nordenstam CG, Narr KL, Khaledy M, Zoumalan CI, Dail R, Kaprio J (2002) Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci USA 99:3228-3233.
28. Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A, Markey CJ, Beshah E, Guroff JJ, Maxwell ME, Kazuba DM, Whiten R, Goldin LR, Gershon ES, Gejman PV (1997) Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 43:1-8.
29. ir2 channels enhances temporal summation of excitatory synaptic potentials in prefrontal cortex pyramidal neurons. J Neurophysiol 97:3432-3438.
30. 1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacol doi:10.1038/sj. npp.1301375.
31. Chapman J (1966) The early symptoms of schizophrenia. Br J Psychiatry 112:225-251.
32. Chaudry HR, Moss HB, Bashir A, Suliman T (1991) Cannabis psychosis following bhang ingestion. Br J Addict 86:1075-1081.
33. 2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533-541.
34. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393-4400.
35. Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM (2007) Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27:791-795.
36. Chen N, Appell M, Berfield JL, Reith ME (2003) Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur J Pharmacol 478:89-95.
37. 2+- dependent intracellular signaling. J Neurophysiol 97:2448-2464.
38. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brainderived neurotrophic factor(BDNF)(Met66) alters the intracellular trafficking and activitydependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24:4401-4411.
39. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37-76.
40. 1): Association with i.v. drug use. Mol Psychiatry 2:161-168.
41. Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180:589-592.
42. 2+ signals by inositol 1, 4, 5-trisphosphate in dopaminergic neurons. J Neurosci 27:4776-4785.
43. Damasio AR (1999) The Feeling of What Happens - Body and Emotion in the Making of Consciousness. New York: Harcourt Brace.
44. Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LL, Parvizi J, Hichwa RD (2000) Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 3:1049-1056.
45. Dawson E (1995) Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 5(S50-S51):850.
46. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis 2:5.
47. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9-15.
48. 1 receptor antagonism increases hippocampal acetylcholine release: Site and mechanism of action. Mol Pharmacol 70:1236-1245.
49. Delmas P, Crest M, Brown DA (2004) Functional organization of PLC signaling microdomains in neurons. Trends Neurosci 27:41-47.
50. Devlin MG, Christopoulos A (2002) Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095-1102.
51. Drewe M, Drewe J, Riecher-Rossler A (2004) Cannabis and risk of psychosis. Swiss Med Wkly 134:659-663.
52. D'Souza DC (2007) Cannabinoids and psychosis. Int Rev Neurobiol 78:289-326.
53. 1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Exp Neurol 204:479-484.
54. Eblen F, Graybiel AM (1995) Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J Neurosci 15:5999-6013.
55. 3K/Akt and Erk signaling pathways and activate proapoptotic function of Bad protein. Cell Signal 17:25-37.
56. Elvevag B, McCormack T, Gilbert A, Brown GD, Weinberger DR, Goldberg TE (2003) Duration judgements in patients with schizophrenia. Psychol Med 33:1249-1261.
57. Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803-807.
58. Freud S (1915) The unconscious. In: Strachey J (ed.), Complete Psychological Works, Vol. 14, translated in 1964. London: Hogarth.
59. Frith CD, Blakemore S, Wolpert DM (2000) Explaining the symptoms of schizophrenia: Abnormalities in the awareness of action. Brain Res Brain Res Rev 31:357-363.
60. Fritzsche M, Fritzsche LN, Kosidubova SM, Prognimak AB, Mayorov OY (2006) Asymmetric information-processing in development, evolution and psychopathology. In: Hellige JB, Bogen JE (eds.), Cognition, Brain, Behavior, Special Issue. Napoca: CBB, pp. 311-342.
61. Fujii N, Graybiel AM (2005) Time-varying covariance of neural activities recorded in striatum and frontal cortex as monkeys perform sequential-saccade tasks. Proc Natl Acad Sci USA 102:9032-9037.
62. Fuster JM (1989) The Prefrontal Cortex, Anatomy, Physiology, and Neuropsychology of the Frontal Lobe. New York: Raven.
63. Gardner EL (2002) Addictive potential of cannabinoids: The underlying neurobiology. Chem Phys Lipids 121:267-290.
64. Gerfen CR (2004) Basal ganglia. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 455-508.
65. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114.
66. Gladkevich A, Kauffman HF, Korf J (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28:559-576.
67. 1 receptor. J Neurosci 17:5327-5333.
68. Goldman-Rakic PS (2005) Working memory dysfunction in schizophrenia. In: Salloway SP, Malloy PF, Duffy JD (eds.), The Frontal Lobes and Neuropsychiatric Illness. Washington, DC: American Psychiatric PI, pp. 71-82.
69. Goto Y, Grace AA (2005a) Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 47:255-266.
70. Goto Y, Grace AA (2005b) Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 8:805-812.
71. Gottesmann C (2006) The dreaming sleep stage: A new neurobiological model of schizophrenia? Neuroscience 140:1105-1115.
72. Green AL, Wang S, Owen SL, Aziz TZ (2007) The periaqueductal grey area and the cardiovascular system. Acta Neurochir Suppl 97:521-528.
73. Gross A, Joutsiniemi SL, Rimon R, Appelberg B (2006) Correlation of symptom clusters of schizophrenia with absolute powers of main frequency bands in quantitative EEG. Behav Brain Funct 2:23.
74. Gu Z, Jiang Q, Yan Z (2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71:1030-1039.
75. Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162-165.
76. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671-676.
77. Hanson DR, Gottesman II (2005) Theories of schizophrenia: A genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7.
78. Häring M, Marsicano G, Lutz B, Monory K (2007) Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146:1212-1219.
79. Harkány T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83-92.
80. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25:372-383.
81. Hashimoto T, Lewis DA (2006) BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 163:534-537.
82. Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L, New A, Siever LJ (2004) Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr Res 71:249-262.
83. Heath RG (1954) Studies in Schizophrenia. A Multidisciplinary Approach to Mind-Brain Relationships. Cambridge: Harvard University Press.
84. Heath RG (1962) Common characteristics of epilepsy and schizophrenia: clinical observation and depth electrode studies. Am J Psychiatry 118:1013-1026.
85. Henquet C, Murray R, Linszen D, van Os J (2005) The environment and schizophrenia: The role of cannabis use. Schizophr Bull 31:608-612.
86. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
87. Herrero MT, Barcia C, Navarro JM (2202) Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 18:386-404.
88. Hicks RE, Gualtieri CT, Mayo JP, Perez-Reyes M (1984) Cannabis, atropine, and temporal information processing. Neuropsychobiology 12:229-237.
89. 1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol 97:2580-2589.
90. Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14- q15. New Biol 3:880-885.
91. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1-10.
92. Holstege G, Mouton LJ, Gerrits N (2004). Emotional motor system. In: Paxinos G (ed.), The Human Nervous System. Amsterdam: Elsevier, pp. 1306-1325.
93. Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: The role of reward-related learning and memory, Annu Rev Neurosci. 2006; 29:565-98.
94. Isohanni M, Miettunen J, Maki P, Murray GK, Ridler K, Lauronen E, Moilanen K, Alaraisanen A, Haapea M, Isohanni I, Ivleva E, Tamminga C, McGrath J, Koponen H (2006) Risk factors for schizophrenia. Follow-up data from the Northern Finland 1966 Birth Cohort Study. World Psychiatry 5:168-171.
95. Iversen L (2003) Cannabis and the brain. Brain 126:1252-1270.
96. Jackson JH (1932) In: Taylor J (ed.), Selected Writings of John Hughlings Jackson. London: Hodder & Stoughton.
97. 1 cannabinoid receptor. J Pharmacol Exp Ther 308:880-886.
98. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- And antidepressantlike effects. J Clin Invest 115:3104-3116.
99. 1 cannabinoid receptor knockout mice. Mol Pharmacol 66:204-208.
100. Jockers-Scherubl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F, Lang UE, Hellweg R (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371:79-83.
101. Jockers-Scherubl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R (2003) Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 17:439-445.
102. Jockers-Scherubl MC, Rentzsch J, Danker-Hopfe H, Radzei N, Schurer F, Bahri S, Hellweg R (2006) Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neurosci Lett 400:262-266.
103. Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116-122.
104. 1) and the P300 event-related potential. Mol Psychiatry 2:169-171.
105. Jones EG (2007) The Thalamus. California: Cambridge University Press.
106. 3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann NY Acad Sci 877:595-613.
107. Kaiya H, Nishida A, Imai A, Nakashima S, Nozawa Y (1989) Accumulation of diacylgylcerol in platelet phosphoinositide turnover in schizophrenia: A biological marker of good prognosis? Biol Psychiatry 26:669-676.
108. Kalkman HO (2006) The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 110:117-134.
109. Kang H, Schuman EM (1995) Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 267:1658-1662.
110. Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
111. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476.
112. 2 receptor occupancy. Arch Gen Psychiatry 57:553-559.
113. Katona I, Sperlágh B, Magloczky Z, Santha E, Köfalvi A, Czirjak S, Mackie K, Vizi ES, Freund TF (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100:797-804.
114. 1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
115. 2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704.
116. Keay KA, Bandler R (2004) Periaqueductal gray. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 244-257.
117. Kim D, Thayer SA (2001) Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 21:RC146.
118. Kimura M, Yamada H, Matsumoto N (2003) Tonically active neurons in the striatum encode motivational contexts of action. Brain Dev Suppl 1:S20-23.
119. Kimura M, Minamimoto T, Matsumoto N, Hori Y (2004) Monitoring and switching of corticobasal ganglia loop functions by the thalamo-striatal system. Neurosci Res 48:355-360.
120. Knusel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, Nikolics K, Hefti F (1991) Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci USA 88:961-965.
121. 1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci Lett 403:151-156.
122. 2+ levels and transmitter release in the hippocampus. Br J Pharmacol 151:551-563.
123. 1Rs in the hippocampus. Annual International Cannabinoid Research Society Meeting, Tihany, Hungary.
124. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci 25:2874-2884.
125. Kolb B, Gorny G, Limebeer CL, Parker LA (2006) Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 60:429-436.
126. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23:195-201.
127. Kraepelin E (1899) Psychiatrie, Dementia praecox. Ein Lehrbuch für Studierende und Aerzte. Leipzig: Barth.
128. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
129. Kristensen K, Cadenhead KS (2007) Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 151:151-154.
130. q/11 G proteins. Proc Natl Acad Sci USA 102:19144-19149.
131. 1): Association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105:749-752.
132. 1E serotonin receptor (S31) (locus HTR1E) to human chromosome 6q14-q15. Genomics 22:637-640.
133. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669.
134. Lewis DA, Hashimoto T (2007) Deciphering the disease process of schizophrenia: The contribution of cortical GABA neurons. Int Rev Neurobiol 78:109-131.
135. Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273-279.
136. Lipska BK (2004) Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282-286.
137. Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31:795-803.
138. Ludwig AM (1966) Altered states of consciousness. Arch Gen Psychiatry 15:225-234.
139. Lupica CR, Riegel AC (2005) Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48:1105-1116.
140. Luria AR (1973) The Working Brain: An Introduction to Neuropsychology. New York: Basic Books.
141. MacDonald III AW, Chafee MV (2006) Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18:853-876.
142. Macleod J, Davey Smith G, Hickman M (2006) Does cannabis use cause schizophrenia? Lancet 367:1055.
143. Maeda K, Sugino H, Hirose T, Kitagawa H, Nagai T, Mizoguchi H, Takuma K, Yamada K (2007) Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 103:299-308.
144. Mäki P, Veijola J, Rantakallio P, Jokelainen J, Jones PB, Isohanni M (2004) Schizophrenia in the offspring of antenatally depressed mothers: A 31-year follow-up of the Northern Finland 1966 Birth Cohort. Schizophr Res 66:79-81.
145. Malaspina D, Dalack G, Leitman D, Corcoran C, Amador XF, Yale S, Glassman A, Gorman JM (2002) Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr 7:53-57.
146. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232.
147. Malone DT, Taylor DA (1999) Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: A microdialysis study in conscious rats. Br J Pharmacol 128:21-26.
148. Mamounas LA, Blue ME, Siuciak JA, Altar CA (1995) Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929 -7939.
149. Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Perez-Hernandez E, Ampuero I, Ramos-Atance JA, Palomo T, Rubio G (2006) (AAT)n repeat in the cannabinoid receptor gene, CNR1: Association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 256:437-441.
150. Massi P, Vaccani A, Parolaro D (2006) Cannabinoids, immune system and cytokine network. Curr Pharm Des 12:3135-3146.
151. Mathers DC, Ghodse AH (1992) Cannabis and psychotic illness. Br J Psychiatry 161:648-653.
152. 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci 7:585-586.
153. Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ (2005) Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 25:11619-11627.
154. McGrath JJ (2006) Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull 32:195-197.
155. McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S, Murray RM (1994) Cannabis and acute psychosis. Schizophr Res 13:161-167.
156. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM (1995) Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15:277-281.
157. Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L (2001) Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 27:53-59.
158. Meck WH (1996) Neuropharmacology of timing and time perception. Cogn Brain Res 3:227-242.
159. Melges FT (1982) Time and the Inner Future - A Temporal Approach to Psychiatric Disorders. New York: Wiley.
160. Melis M, Gessa GL, Diana M (2000) Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24:993-1006.
161. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M (2004a) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707-10715.
162. 1 receptors. J Neurosci 24:53-62.
163. Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR (2007) Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 117:672-682.
164. Minamimoto T, Hori Y, Kimura M (2005) Complementary process to response bias in the centromedian nucleus of the thalamus. Science 308:1798-1801.
165. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6:293-301.
166. Misslin R (2003) The defense system of fear: behavior and neurocircuitry. Neurophysiol Clin 33:55-66.
167. Moreira FA, Guimarães FS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512:199-205.
168. 1/NMDA-NR1 and CaMKII pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol doi:10.1124/mol.106.032961.
169. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ (2000) Immune system and schizophrenia. An integrative view. Ann NY Acad Sci 917:456-467.
170. Munson R, Ruchkin DS, Ritter W, Sutton S, Squires NK (1984) The relation of P3b to prior events and future behavior. Biol Psychol 19:1-29.
171. Narr KL, Bilder RM, Toga AW, Woods RP, Rex DE, Szeszko PR, Robinson D, Sevy S, Gunduz- Bruce H, Wang YP, DeLuca H, Thompson PM (2005a) Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb Cortex 15:708-719.
172. Narr KL, Cannon TD, Woods RP, Thompson PM, Kim S, Asunction D, van Erp TG, Poutanen VP, Huttunen M, Lonnqvist J, Standerksjold-Nordenstam CG, Kaprio J, Mazziotta JC, Toga AW (2002) Genetic contributions to altered callosal morphology in schizophrenia. J Neurosci 22:3720-3729.
173. Narr KL, Thompson PM, Szeszko P, Robinson D, Jang S, Woods RP, Kim S, Hayashi KM, Asunction D, Toga AW, Bilder RM (2004) Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage 21:1563-1575.
174. Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, Sevy S, Wang Y, Schrock K, Bilder RM (2005b) Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol Psychiatry 58:32-40.
175. Narushima M, Uchigashima M, Fukaya M, Matsui M, Manabe T, Hashimoto K, Watanabe M, Kano M (2007) Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J Neurosci 27:496-506.
176. Negrete JC (1989) Cannabis and schizophrenia. Br J Addict 84:349-351.
177. Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556-560.
178. Nieuwenhuys R, Voogd J, van Huijzen Ch (1988) The Human Central Nervous System. Berlin: Springer.
179. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proofof- concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638.
180. Olincy A, Johnson LL, Ross RG (2003) Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 117:223-236.
181. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
182. Ouimet CC, Langley-Guillion KC, Greengard P (1998) Quantitative immunochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 808:8-12.
183. Oz M, Ravindran R, Zhang L, Morales M (2003) Endogenous cannabinoid, anandamide inhibits neuronal nicotinic acethylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306:1003-1010.
184. Oz M, Zhang L, Ravindran A, Morales M, Lupica CR (2004) Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. J Pharmacol Exp Ther 310:1152-1160.
185. 1a. J Neurochem 84:592-601.
186. Pereira DB, Rebola N, Rodrigues RJ, Cunha RA, Carvalho AP, Duarte CB (2006) Trkb receptors modulation of glutamate release is limited to a subset of nerve terminals in the adult rat hippocampus. J Neurosci Res 83:832-844.
187. Pertwee RG (2006) Cannabinoid pharmacology: The first 66 years. Br J Pharmacol 147: S163-S171.
188. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34.
189. Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14:96-102.
190. 1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 8:466-467.
191. Power JM, Sah P (2007) Distribution of IP3-mediated calcium responses and their role in nuclear signaling in rat basolateral amygdala neurons. J Physiol 580:835-857.
192. 1- independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 101:389-396.
193. Price G, Cercignani M, Parker GJ, Altmann DR, Barnes TR, Barker GJ, Joyce EM, Ron MA (2007) Abnormal brain connectivity in first-episode psychosis: A diffusion MRI tractography study of the corpus callosum. Neuroimage 35:458-466.
194. Pryor SR (2000) Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Med Hypotheses 55:494-501.
195. Ragozzino ME, Choi D (2004) Dynamic changes in acetylcholine output in the medial striatum during place reversal learning. Learn Mem 11:70-77.
196. q/11 in the striatum. Proc Natl Acad Sci USA 104:654-659.
197. Risold PY (2004) The septal region. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 602-636.
198. Rizzolatti G, Gallese V (2003) Mirror neurons. In: Nadel L (ed.), Encyclopedia of Cognitive Science. London: Nature PG, Vol. III, pp. 37-42.
199. Ronesi J, Lovinger DM (2005) Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol 562:245-256.
200. Roopun AK, Middleton SJ, Cunningham MO, LeBeau FE, Bibbig A, Whittington MA, Traub RD (2006) A beta2-frequency (20-30 Hz) oscillation in nonsynaptic networks of somatosensory cortex. Proc Natl Acad Sci USA 103:15646-15650.
201. Samejima K, Ueda Y, Doya K, Kimura M (2005) Representation of action-specific reward values in the striatum. Science 310:1337-1340.
202. Sarter M, Bruno JP (2000) Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 95:933-952.
203. Saulskaya NB (2000) Volume transmission in the striatum as constituting information processing In: Miller R, Ivanitsky AM, Balaban PM (eds.), Complex Brain Functions - Conceptual Advances in Russian Neuroscience. Singapore: OPA, pp. 1-19.
204. Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 175:641-652.
205. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
206. Semple DM, McIntosh AM, Lawrie SM (2005) Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol 19:187-194.
207. Semple DM, Ramsden F, McIntosh AM. (2003) Reduced binocular depth inversion in regular cannabis users. Pharmacol Biochem Behav 75:789-793.
208. Shapovalova KB (2000) The striatal cholinergic system and instrumental behaviour. In: Miller R, Ivanitsky AM, Balaban PM (eds.), Complex Brain Functions - Conceptual Advances in Russian Neuroscience. Singapore: OPA, pp. 263-288.
209. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson RA, Sagar SM (1994) Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62:1079-1092.
210. Shearn CR, Fitzgibbons DJ (1972) Patterns of drug use in a population of youthful psychiatric patients. Am J Psychiatry 128:1381-1387.
211. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A review of MRI findings in schizophrenia. Schizophr Res 49:1-52.
212. Shergill SS, Samson G, Bays PM, Frith CD, Wolpert DM (2005) Evidence for sensory prediction deficits in schizophrenia. Am J Psychiatry 162:2384-2386.
213. Simmons JM, Richmond BJ (2007) Dynamic changes in representations of preceding and upcoming reward in monkey orbitofrontal cortex. Cereb Cortex doi:10.1093/cercor/bhm034.
214. Simonyi A, Schachtman TR, Christoffersen GR (2005) The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18:353-361.
215. Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF (2006) Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 163:1798-1805.
216. Smesny S, Rosburg T, Baur K, Rudolph N, Sauer H (2007) Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology 32:2067-2073.
217. Solowij N, Michie PT (2007) Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30-52.
218. Solowij N, Michie PT, Fox AM (1991) Effect of long-term cannabis use on selective attention: An event-related potential study. Pharmacol Biochem Behav 40:683-688.
219. +-ATPase. Neurochem Int 44:529-538.
220. Stein BE, Meredith MA (1993) The Merging of the Senses. Cambridge: MIT.
221. Suh BC, Hille B (2007) Regulation of KCNQ channels by manipulation of phosphoinositides. J Physiol 582:911-916.
222. 3H]CP55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371:428-433.
223. 2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235.
224. Swanson LW (2000) Cerebral hemisphere regulation of motivated behavior. Brain Res 886:113-164.
225. Szabo B, Siemes S, Wallmichrath I (2002) Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 15:2057-2061.
226. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM (2007) Anterior cingulate greymatter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry 190:230-236.
227. Talbot K, Arnold SA (2002) The parahippocampal region in schizophrenia. In: Witter M, Wouterlood F (eds.), The Parahippocampal Region - Organization and Role in Cognitive Function. Oxford: Oxford University Press, pp. 297-320.
228. Tappe A, Kuner R (2006) Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. Proc Natl Acad Sci USA 103:774-779.
229. Tendolkar I, Weis S, Guddat O, Fernandez G, Brockhaus-Dumke A, Specht K, Klosterkotter J, Reul J, Ruhrmann S (2004) Evidence for a dysfunctional retrosplenial cortex in patients with schizophrenia: A functional magnetic resonance imaging study with a semantic-perceptual contrast. Neurosci Lett 369:4-8.
230. 1) polymorphism and schizophrenia. Psychiatr Genet 10:149-151.
231. Turner WM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16:87-95.
232. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007) Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27:3663-3676.
233. Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96:376-381.
234. 1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515-518.
235. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002) Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 156:319-327.
236. Vignal JP, Maillard L, McGonigal A, Chauvel P (2007) The dreamy state: hallucinations of autobiographic memory evoked by temporal lobe stimulations and seizures. Brain 130:88-99.
237. Virchow R (1847) Standpoints in scientific medicine. In: Rather LJ (ed.), Diseases, Life and Man; Selected Essays by Rudolf Virchow. Stanford: Stanford University Press.
238. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG (2001) Cannabis induced dopamine release: An in-vivo SPECT study. Psychiatry Res 107:173-177.
239. 2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci USA 101:5093-5098.
240. Weiser M, Knobler HY, Noy S, Kaplan Z (2002) Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114:949-955.
241. Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81-85.
242. q/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol 26:5888-5894.
243. Yamasue H, Iwanami A, Hirayasu Y, Yamada H, Abe O, Kuroki N, Fukuda R, Tsujii K, Aoki S, Ohtomo K, Kato N, Kasai K (2004) Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: An MRI parcellation study. Psychiatry Res 131:195-207.
244. Yano M, Steiner H (2005) Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132:855-865.
245. Yeomans JS (1995) Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12:3-16.
246. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325:1199.
247. 1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355-360.
248. Zhang PW, Isighuro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR (2004) Human cannabinoid receptor 1:5¢ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysusbstance abuse. Mol Psychiatry 9:916-931.
249. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421-429.
250. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56:485-486.